231 related articles for article (PubMed ID: 32239677)
21. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J
Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298
[TBL] [Abstract][Full Text] [Related]
22. Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically Resected Thalamic Gliomas in Children.
Chiba K; Aihara Y; Masui K; Abe K; Komori T; Kawamata T
World Neurosurg; 2020 Feb; 134():e530-e539. PubMed ID: 31704359
[TBL] [Abstract][Full Text] [Related]
23. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
24. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
25. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
27. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.
Youland RS; Kreofsky CR; Schomas DA; Brown PD; Buckner JC; Laack NN
J Neurooncol; 2017 Dec; 135(3):535-543. PubMed ID: 28836106
[TBL] [Abstract][Full Text] [Related]
28. Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG).
Mirow C; Pietsch T; Berkefeld S; Kwiecien R; Warmuth-Metz M; Falkenstein F; Diehl B; von Hornstein S; Gnekow AK
Pediatr Blood Cancer; 2014 Mar; 61(3):457-63. PubMed ID: 24039013
[TBL] [Abstract][Full Text] [Related]
29. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
30. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
31. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
Kai Z; Dingyang L; Zhuanyi Y
World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
[TBL] [Abstract][Full Text] [Related]
33. Benign Glioma.
Wu PB; Filley AC; Miller ML; Bruce JN
Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934
[TBL] [Abstract][Full Text] [Related]
34. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.
Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K
Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
36. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project.
Pala A; Nadji-Ohl M; Faust K; Rückriegel S; Roder C; von der Brelie C; Forster MT; Löbel F; Schommer S; Löhr M; Renovanz M; Grübel N; Rothenbacher D; König R; Engelke J; Schmitz B; Wirtz CR; Ringel F; Senft C; Rohde V; Tatagiba M; Ernestus RI; Vajkoczy P; Ganslandt O; Nagel G; Coburger J
J Neurol Surg A Cent Eur Neurosurg; 2020 Jan; 81(1):48-57. PubMed ID: 31550737
[TBL] [Abstract][Full Text] [Related]
37. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
38. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of centrally located low-grade glioma in children.
Terashima K; Chow K; Jones J; Ahern C; Jo E; Ellezam B; Paulino AC; Okcu MF; Su J; Adesina A; Mahajan A; Dauser R; Whitehead W; Lau C; Chintagumpala M
Cancer; 2013 Jul; 119(14):2630-8. PubMed ID: 23625612
[TBL] [Abstract][Full Text] [Related]
40. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
